Unoprostone as adjunctive therapy to timolol: A double masked randomised study versus brimonidine and dorzolamide

British Journal of Ophthalmology

Volumn 87, Issue 5, 2003, Pages 592-598

  Hommer, A ^b   Kapik, B ^a   Shams, Naveed ^a  

^a Novartis Ophthalmics Inc   (United States)

^b Krankenanstalt Sanatorium Hera   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BRIMONIDINE; DORZOLAMIDE; TIMOLOL MALEATE; UNOPROSTONE ISOPROPYL ESTER;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA INJURY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOREIGN BODY SENSATION; HEADACHE; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LACRIMATION DISORDER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN ANGLE GLAUCOMA; PERSONALITY DISORDER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETINA ARTERY OCCLUSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TASTE PERVERSION; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHEMOTHERAPY, ADJUVANT; DINOPROST; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; QUINOXALINES; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 0038070178     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.87.5.592     Document Type: Article

References (70)

1. Quigley HA. Recognizing structural damage to the optic nerve head and nerve fiber layer in glaucoma (letter). Am J Ophthalmol 1998;125:563; discussion 564-5.
2. Orgül S, Gugleta K, Flammer J. Physiology of perfusion as it relates to the optic nerve head. Surv Ophthalmol 1999;43(Suppl 1):S17-26.
3. Anderson DR. Introductory comments on blood flow autoregulation in the optic nerve head and vascular risk factors in glaucoma. Surv Ophthalmol 1999;43(Suppl 1):S5-9.
4. Flammer J, Haefliger IO, Orgül S, et al. Vascular dysregulation: a principal risk factor for glaucomatous damage? J Glaucoma 1999;8:212-19.
5. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001;20:319-49.
6. Schmidt KG, Klingmüller V, von Rückmann A, et al. Retrobulbäre und chorioidale Hämodynamik bei Hochdruck- und Normaldruckglaukom. In: Schmidt KG, Pillunat LE, eds. Fortbildung glaukom. Stuttgart: Enke, 2000:103-14.
7. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000;59:411-34.
8. Neuringer M. Infant vision and retinal function in studies of dietary long-chain polyunsaturated fatty acids: methods, results, and implications. Am J Clin Nutr 2000;71 (Suppl):256S-7S.
9. Kim HY, Edsall L. The role of docosahexaenoic acid (22:6n-3) in neuronal signaling. Lipids 1999;34[Suppl]:S249-50.
10. Rotstein NP, Aveldano MI, Barrantes FJ, et al. Apoptosis of retinal photoreceptors during development in vitro: protective effect of docosahexaenoic acid. J Neurochem 1997;69:504-13.
11. Rotstein NP, Politi LE, Aveldano MI. Docosahexaenoic acid promotes differentiation of developing photoreceptors in culture. Invest Ophthalmol Vis Sci 1998;39:2750-8.
12. Uauy R, Birch E, Birch D, et al. Visual and brain function measurements in studies of n-3 fatty acid requirements of infants. J Pediatr 1992;120(Pt 2):S168-80.
13. Hoffman DR, Birch EE, Birch DG, et al. Effects of supplementation with omega 3 long-chain polyunsaturated fatty acids on retinal and cortical development in premature infants. Am J Clin Nutr 1993;57(Suppl):807S-12S.
14. Bazan NG, Rodriguez de Turco EB. Review: pharmacological manipulation of docosahexaenoic-phospholipid biosynthesis in photoreceptor cells: implications in retinal degeneration. J Ocul Pharmacol 1994;10:591-604.
15. Bell MV, Batty RS, Dick JR, et al. Dietary deficiency of docosahexaenoic acid impairs vision at low light intensities in juvenile herring (Clupea harengus L). Lipids 1995;30:443-9.
16. Rotstein NP, Aveldano MI, Barrantes FJ, et al. Docosahexaenoic acid is required for the survival of rat retinal photoreceptors in vitro. J Neurochem 1996;66:1851-9.
17. Talesnik J. Arachidonic acid induced coronary reactions and their inhibition by docosahexaenoic acid. Can J Physiol Pharmacol 1986;64:77-84.
18. Engler MB, Karanian JW, Salem N Jr. Docosahexaenoic acid (22:6n3)-induced relaxation of the rat aorta. Eur J Pharmacol 1990;185:223-6.
19. Fleischhauer FJ, Yan WD, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol 1993;21:982-9.
20. Mano MT, Bexis S, Abeywardena MY, et al. Fish oils modulate blood pressure and vascular contractility in the rat and vascular contractility in the primate. Blood Press 1995;4:177-86.
21. Engler MB, Engler MM. Docosahexaenoic acid-induced vasorelaxation in hypertensive rats: mechanisms of action. Biol Res Nurs 2000;2:85-95.
22. Sugiyama T, Azuma I. Effect of UF-021 on optic nerve head circulation in rabbits. Jpn J Ophthalmol 1995;39:124-9.
23. Questel I, Pages C, Lambrou GN, et al. Effects of unoprostone isopropyl in ocular blood flow decrease induced by systemic vasoconstrictor administration in cynomolgus monkeys (abstract). Invest Ophthalmol Vis Sci 2000;41:5560.
24. Yu DY, Su EN, Cringle SJ, et al. Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci 2001;42:1499-504.
25. Polska EA, Doelemeyer A, Ehrlich P, et al. Topical unoprostone isopropyl partially antagonizes endothelin-1-induced vasoconstriction in the human choroid. Arch Ophthalmol (in press).
26. Ogo T. Effect of isopropyl unoprostone on choroidal circulation - changes in choroidal blood flow and intraocular pressure with topical application. Ganki 1996;47:268-72.
27. Kojima S, Sugiyama T, Azuma I, et al. Effect of topically applied isopropyl unoprostone on microcirculation in the human ocular fundus evaluated with a laser speckle microcirculation analyser. Nippon Ganka Gakkai Zasshi 1997;101:605-10.
28. Makimoto Y, Sugiyama T, Kojima S, et al. Long-term effect of topically applied isopropyl unoprostone on microcirculation in the choroid-retina. Nippon Ganka Gakkai Zasshi 2000;104:39-43.
29. Nishi A, Emi K, Ito Y, et al. The change of ocular blaod flow after topical instillation of unoprostone eye drops (abstract). Invest Ophthalmol Vis Sci 1997;3B:3600.
30. Nishimura T, Okamoto N. Changes in ocular blood circulation after six months treatment with isopropyl unoprostone (Rescula) in patients with normal tension glaucoma (abstract). In: Book of Abstracts. 28th International Conference of Ophthalmology. Amsterdam: Netherlands 1998 (21-26 June);140(P6.086).
31. LaFuente MP, Mayor-Torroglosa S, Villagas-Perez M, et al. Retinal ganglion cell survival after transient ligation of the ophthalmic vessels and administration of unoprostone isopropyl (abstract). Invest Ophthalmol Vis Sci 2000;41:S15.
32. Hayami K, Unoki K. Photoreceptor pratection against constant light-induced damage by isopropyl unoprostone, a prostaglandin F2a metabolite-related compound. Ophthalmic Res 2001;33:203-9.
33. Hiida Y, Kishimoto N, Deguchi T. Protective effects against light damage to the photoreceptor by topical application with isopropyl unoprostone ophthalmic solution (abstract). Invest Ophthalmol Vis Sci 1999;40:S953.
34. Marcheselli VL, DeCoster MA, Campbell Z, et al. Neuroprotection by unoprostone, but not by latanoprost, against glutamate-stimulated calcium influx and cell death in retinal ganglion cells (abstract). Invest Ophthalmol Vis Sci 2001;42:S750.
35. Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol 1997;41 (Suppl 2):S61-8.
36. Haria M, Spencer CM. Unoprostone (isopropyl unoprostone). Drugs Aging 1996;9:213-18; discussion 219-20.
37. Wiederholt M, Thieme H, Stumpff F, et al. Mechanisms of action of unoprostone (Rescula) on contractility of the trabecular meshwork (abstract). Invest Ophthalmol Vis Sci 2001;42:S835.
38. Yoshida S, Deguchi T, Osama H, et al. The mechanism of IOP lowering action of Rescula, a new therapeutic agent for glaucoma and ocular hypertension in various animals- comparison with prostaglandin F2a. The Clinical Report 1994;28:3827-38.
39. Yuguchi M. Ocular hypotensive action of isopropyl unoprostone. J Eye 1998;15:987-90.
40. Taniguchi T, Haque MS, Sugiyama K, et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther 1996;12:489-98.
41. Balfour JA, Wilde MI. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension. Drugs Aging 1997;10:384-403.
42. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995;113:1514-17.
43. Mello A, et al. Safety of unoprostone isopropyl 0.15% as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension. (submitted for publication).
44. Suzuki Y, Shirato S, Adachi M, et al. Risk factors for the progression of treated primary open-angle glaucoma: a multivariate life-table analysis. Graefes Arch Clin Exp Ophthalmol 1999;237:463-7.
45. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983;118:166-91.
46. Lundberg L, Wettrell K, Linner E. Ocular hypertension. A prospective twenty-year follow-up study. Acta Ophthalmol (Copenh) 1987;65:705-8.
47. Van Veldhuisen PC, Ederer F, Gaasterland DE, et al. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40.
48. Drance S, Anderson DR, Schultzer M, et al. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699-708
49. Nakamatsu T, Okinami S, Oono S. The ocular hypotensive effect of concomitant use of isopropyl unoprostone (Rescula) and timolol. J Eye 1996;13:439-41.
50. Azuma I. Clinical evaluation of UF-021 ophthalmic solution in glaucoma patients refractory to maximum tolerable therapy. Nippon Ganka Gakkai Zasshi 1993;97:232-8.
51. Motegi Y, Araie M, Suzuki Y, et al. Clinical study of UF-021 (Rescula) ophthalmic solution in refractory glaucoma. Ganki 1993;44:12-18.
52. Shiose Y. Clinical study of UF-021 (Rescula) ophthalmic solution, a novel metabolite-type prostaglandin for the treatment of glaucoma and ocular hypertension. J Eye 1993;10:1761-7.
53. Yamamoto T, Chi Q, Kitazawa Y. Interaction between a prostaglandin F2 alpha derivative, UF-021, and pilocarpine in ocular hypotensive therapy. Nippon Ganka Gakkai Zasshi 1994;98:202-5.
54. Stewart WC, Sharpe ED, Stewart JA, et al. Additive efficacy of unoprostone isopropyl 0.12% (Rescula) to latanoprost 0.005%. Am J Ophthalmol 2001;131:339-44.
55. Azuma I, Masuda K, Kitazawa K, et al. Phase II double-masked dose-determination study of UF-021 (Rescula) ophthalmic solution in primary open-angle glaucoma and ocular hypertension. Ganki 1992;43:1425-31.
56. Takase M, Nanba H, Kato M, et al. Early phase II clinical study of UF-021 ophthalmic solution in primary open-angle glaucoma or ocular hypertension patients. J Eye 1992;9:1917-25.
57. Azuma I, Masuda K, Kitazawa Y, et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-25.
58. Fujimori C, Yamabayashi S, Hosoda M, et al. The clinical evaluation of UF-021, a new prostaglandin related compound, in low tensian glaucoma patients. Nippon Ganka Gakkai Zasshi 1993;97:1231-5.
59. Yamamoto T, Kitazawa Y, Azuma I, et al. Clinical evaluation of UF-021 (Rescula®; isopropyl unoprostone). Surv Ophthalmol 1997;41 (suppl 2):S99-103.
60. Stewart WC, Stewart JA, Kapik BM. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure. J Glaucoma 1998;7:388-94.
61. Nordmann JP, Rouland JF, Mertz BP. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension. Curr Med Res Opin 1999;15:87-93.
62. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41 (Suppl 1):S27-37.
63. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20-6.
64. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-52.
65. Camras CB, The United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
66. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-37.
67. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41 (Suppl 2):S129-38.
68. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997;6:430-2.
69. Sorbera LA, Leeson PA, Rabasseda X, et al. Bimatoprost antiglaucoma (AGN-192024). Drugs Future 2001;26:433-9.
70. Melamed S, Nordmann J, Yannoulis N, et al. The efficacy and safety of unoprostone isopropyl 0.15%, timolol maleate 0.5%, and betaxolol hydrochloride 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Month 12 data. Invest Ophthalmol Vis Sci 2001;42:S556.